Inventiva (NASDAQ:IVA) Stock Price Down 0.7% – Here’s What Happened

Inventiva S.A. (NASDAQ:IVA) shares dropped 0.7% during mid-day trading on Friday . The company traded as low as $2.74 and last traded at $2.98. Approximately 6,833 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 66,689 shares. The stock had previously closed at $3.00.

Wall Street Analyst Weigh In

IVA has been the subject of a number of research reports. Stifel Nicolaus cut their price objective on Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, November 22nd. TD Cowen began coverage on Inventiva in a research note on Friday, February 21st. They issued a “buy” rating and a $10.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Inventiva in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Stock Down 0.7 %

The business has a 50 day moving average price of $2.56 and a two-hundred day moving average price of $2.44.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.